HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership, and institutional investors. According to the company, the net proceeds will be used to fund commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of artificial intelligence capabilities, and for general corporate purposes.
The offering represents a significant milestone for HeartBeam as it transitions from product development to commercial stage. The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed to enable cable-free cardiac monitoring. HeartBeam's platform collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a standard 12-lead ECG, allowing physicians to identify cardiac health trends and acute conditions remotely.
HeartBeam holds over 20 issued patents related to its technology enablement. The company's vision is to redefine cardiac health management by enabling patients to receive actionable heart intelligence outside of medical facilities. With the new funding, HeartBeam aims to accelerate market adoption of its devices, which are intended for portable use wherever the patient is located.
The full press release is available at https://ibn.fm/9iNYY. For more information about HeartBeam, visit the company's newsroom at https://ibn.fm/BEAT.
This announcement underscores the growing interest in remote cardiac monitoring solutions, particularly those that can provide comprehensive diagnostic data without the need for traditional wired ECG systems. The successful capital raise positions HeartBeam to compete in the expanding market for digital health technologies aimed at reducing healthcare costs and improving patient outcomes.
